Takeda Partners with Sun Pharma and Cipla for Vonoprazan Commercialization in India
Takeda gives Sun Pharma and Cipla non-exclusive rights to sell gastrointestinal drug Vonoprazan in India.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
Japan's Takeda Pharmaceutical has granted Sun Pharmaceutical
and Cipla the rights to commercialize Vonoprazan, a gastrointestinal drug, in
India. Vonoprazan, sold as tablets under the brand name "Voltapraz,"
blocks a crucial step in stomach acid production, according to Sun Pharma's
announcement on Friday. Cipla shared the agreement a day earlier.
Takeda has provided both companies with non-exclusive patent
licensing rights for the drug, aimed at treating gastroesophageal reflux
disease (GERD), which affects 5% to 28.5% of India's population.
Earlier this month, Torrent Pharmaceuticals also struck a
deal with Takeda to market Vonoprazan in the Indian market, expanding the
availability of this treatment for GERD patients.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Ab Science rivede i tempi dei trial dopo tre ispezioni GCP
Novo Nordisk Firma un Accordo da $2.6B con Hengrui per GLP-1 Orale
Discussion